Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
47,000
Employees47,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
47,000
Employees47,000

LLY Key Statistics

Market cap
876.82B
Market cap876.82B
Price-Earnings ratio
45.79
Price-Earnings ratio45.79
Dividend yield
0.63%
Dividend yield0.63%
Average volume
4.27M
Average volume4.27M
High today
$943.50
High today$943.50
Low today
$916.26
Low today$916.26
Open price
$927.80
Open price$927.80
Volume
895.46K
Volume895.46K
52 Week high
$955.46
52 Week high$955.46
52 Week low
$623.78
52 Week low$623.78

Stock Snapshot

With a market cap of 876.82B, Eli Lilly(LLY) trades at $927.47. The stock has a price-to-earnings ratio of 45.79 and currently yields dividends of 62.6%.

During the trading session on 2025-11-06, Eli Lilly(LLY) shares reached a daily high of $943.50 and a low of $916.26. At a current price of $927.47, the stock is +1.2% higher than the low and still -1.7% under the high.

Trading volume for Eli Lilly(LLY) stock has reached 895.46K, versus its average volume of 4.27M.

Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $955.46 and a low of $623.78.

Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $955.46 and a low of $623.78.

LLY News

Nasdaq 55m
Lilly's Obesity Drug Eloralintide Meets Primary Goal In Phase 2 Study

(RTTNews) - Eli Lilly and Company (LLY) on Thursday announced positive results from a Phase 2 trial evaluating eloralintide in adults with obesity or overweight...

Lilly's Obesity Drug Eloralintide Meets Primary Goal In Phase 2  Study
TipRanks 2h
Eli Lilly announces positive results from Phase 2 trial of eloralintide

Eli Lilly (LLY) “announced positive results from a Phase 2 trial evaluating the safety and efficacy of eloralintide, an investigational once-weekly, selective a...

CNBC 3h
Eli Lilly to start late-stage trials on amylin obesity drug after it shows up to 20% weight loss in study

Eli Lilly on Thursday said it will start late-stage trials on its experimental amylin obesity drug next month after it showed encouraging results in a mid-stage...

Eli Lilly to start late-stage trials on amylin obesity drug after it shows up to 20% weight loss in study

Analyst ratings

77%

of 31 ratings
Buy
77.4%
Hold
19.4%
Sell
3.2%

More LLY News

Benzinga 21h
Stocks Rebound, Eli Lilly Jumps To 14-Month Highs: What's Moving Markets Wednesday?

Wall Street bounced back Wednesday after Tuesday's sharp selloff in AI-driven stocks, as investors bought the dip amid solid corporate earnings and growing sign...

Stocks Rebound, Eli Lilly Jumps To 14-Month Highs: What's Moving Markets Wednesday?
Nasdaq 22h
How To YieldBoost LLY From 0.6% To 6% Using Options

Shareholders of Eli Lilly (Symbol: LLY) looking to boost their income beyond the stock's 0.6% annualized dividend yield can sell the January 2028 covered call a...

How To YieldBoost LLY From 0.6% To 6% Using Options
TipRanks 22h
Novo Nordisk Stock Falls after Medicare Price Deal and Q3 Earnings Miss

Shares of Novo Nordisk (NVO) fell on Wednesday morning after the Danish drugmaker agreed to a price deal under the U.S. Medicare program for the active ingredie...

TipRanks 24h
Eli Lilly Stock Rises as Competitor Novo Nordisk Cuts Guidance

Eli Lilly’s stock (LLY) is trending higher on Nov. 5 after archrival Novo Nordisk (NVO) lowered its growth outlook for its competing weight-loss drugs. Elevate...

The Motley Fool 1d
This Company Now Has the World's No. 1 Drug. Should You Invest $1,000?

Lilly's GLP-1 drug became the best-selling drug on Earth in the third quarter. Eli Lilly (LLY +1.13%) manufactures a drug called tirzepatide, a GLP-1 dual rece...

This Company Now Has the World's No. 1 Drug. Should You Invest $1,000?
TipRanks 1d
XtalPi’s Ailux Partners with Eli Lilly for AI-Driven Antibody Development

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...

Nasdaq 2d
Billionaire Stanley Druckenmiller Dropped Nvidia and Palantir Stock and Is Piling into 2 Stocks Set to Win in One of the Decade's Hottest Growth Markets.

Key Points Stanley Druckenmiller has a fantastic investing track record, delivering a double-digit average annual return over time. The billionaire sold artif...

Billionaire Stanley Druckenmiller Dropped Nvidia and Palantir Stock and Is Piling into 2 Stocks Set to Win in One of the Decade's Hottest Growth Markets.

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.